Whole-exome sequencing by The Cancer Genome Atlas (TCGA) program has confirmed earlier work, showing that gain of function mutations in PIK3CA and AKT1, and inactivating mutations in PTEN are common in ER+ breast cancer (32–49%, 13–24%, and approximately 7% respectively) [50–52]. This evidence concerns the gene AKT1 and breast carcinoma.